See more : M.V.K. AGRO FOOD P (MVKAGRO-ST.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Microbot Medical Inc. (MBOT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Microbot Medical Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Shinyoung Securities Co., Ltd. (001725.KS) Income Statement Analysis – Financial Results
- Reliance Industrial Infrastructure Limited (RIIL.NS) Income Statement Analysis – Financial Results
- Tlou Energy Limited (TLOU.L) Income Statement Analysis – Financial Results
- Xinjiang Tianrun Dairy Co., Ltd. (600419.SS) Income Statement Analysis – Financial Results
- Hengli Industrial Development Group Co., Ltd. (000622.SZ) Income Statement Analysis – Financial Results
Microbot Medical Inc. (MBOT)
Industry: Medical - Instruments & Supplies
Sector: Healthcare
Website: https://www.microbotmedical.com
About Microbot Medical Inc.
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio. It has 42 issued/allowed patents and 23 patent applications pending worldwide. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 117.00K | 1.01M | 1.20M | 1.37M | 1.22M | 1.43M | 992.87K | 231.73K | 56.72K | 92.85K | 205.91K | 141.03K | 273.43K | 415.38K | 805.23K | 74.30K | 5.02M | 8.80M | 10.60M | 7.10M | 11.80M | 1.30M | 3.00M | 1.40M | 500.00K |
| Cost of Revenue | 106.00K | 102.00K | 76.00K | 68.00K | 84.00K | 54.00K | 21.00K | 10.00K | 17.00K | 0.00 | 316.00K | 263.19K | 215.00K | 168.42K | 261.44K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.78M | -2.05M | -2.80M | 16.50M | -1.80M | -1.50M | -1.80M | 10.30M | 7.40M | 4.70M |
| Gross Profit | -106.00K | -102.00K | -76.00K | -68.00K | -84.00K | -54.00K | -21.00K | -10.00K | 100.00K | 1.01M | 887.00K | 1.10M | 1.01M | 1.26M | 731.43K | 231.73K | 56.72K | 92.85K | 205.91K | 141.03K | 273.43K | 415.38K | 805.23K | 2.86M | 7.07M | 11.60M | -5.90M | 8.90M | 13.30M | 3.10M | -7.30M | -6.00M | -4.20M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 85.47% | 100.00% | 73.73% | 80.76% | 82.39% | 88.20% | 73.67% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 3,845.92% | 140.75% | 131.82% | -55.66% | 125.35% | 112.71% | 238.46% | -243.33% | -428.57% | -840.00% |
| Research & Development | 5.62M | 7.74M | 6.15M | 3.40M | 3.05M | 2.52M | 1.10M | 901.00K | 27.11M | 21.50M | 20.53M | 15.85M | 19.94M | 21.02M | 19.93M | 17.81M | 19.94M | 13.60M | 8.93M | 8.76M | 6.14M | 6.40M | 8.60M | 5.98M | 9.98M | 17.70M | 0.00 | 17.10M | 14.70M | 13.50M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 4.13M | 5.43M | 5.09M | 5.56M | 4.03M | 4.50M | 4.01M | 8.73M | 9.33B | 65.11 | 44.17 | 0.00 | 0.00 | 0.00 | 0.00 | 8.30M | 7.93B | 7.15B | 4.84B | 3.95B | 3.39B | 4.23B | 3.79M | 3.36M | 4.93M | 4.60M | 6.20M | 5.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 23.00K | 26.00K | 180.00K | -9.32B | 10.42M | 8.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -7.92B | -7.15B | -4.83B | -3.95B | -3.38B | -4.22B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.13M | 5.43M | 5.09M | 5.56M | 4.03M | 4.52M | 4.04M | 8.73M | 9.33M | 10.42M | 8.90M | 7.45M | 8.20M | 9.38M | 9.53M | 8.30M | 7.93M | 7.15M | 7.66M | 6.78M | 6.28M | 4.23M | 3.79M | 3.36M | 4.93M | 4.60M | 6.20M | 5.70M | 4.60M | 4.70M | 3.40M | 2.90M | 1.80M |
| Other Expenses | 0.00 | 120.00K | 112.00K | 130.00K | 165.00K | 205.00K | 130.00K | -180.00K | 130.00K | -46.00K | 68.00K | 33.69K | 727.27M | 53.57M | 649.61K | 866.20M | 783.02M | 709.21K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.78M | 2.05M | 2.80M | 2.10M | 1.80M | 1.50M | 1.80M | 1.50M | 800.00K | 400.00K |
| Operating Expenses | 9.86M | 13.28M | 11.36M | 9.09M | 7.24M | 7.24M | 5.27M | 9.64M | 36.45M | 31.92M | 29.43M | 23.29M | 28.14M | 30.40M | 30.11M | 26.10M | 27.86M | 21.46M | 16.59M | 15.54M | 12.42M | 10.63M | 12.39M | 12.12M | 16.96M | 25.10M | 8.30M | 24.60M | 20.80M | 20.00M | 4.90M | 3.70M | 2.20M |
| Cost & Expenses | 9.86M | 13.28M | 11.36M | 9.09M | 7.24M | 7.24M | 5.27M | 9.64M | 36.45M | 31.92M | 29.75M | 23.56M | 28.36M | 30.56M | 30.37M | 26.10M | 27.86M | 21.46M | 16.59M | 15.54M | 12.42M | 10.63M | 12.39M | 9.34M | 14.91M | 22.30M | 24.80M | 22.80M | 19.30M | 18.20M | 15.20M | 11.10M | 6.90M |
| Interest Income | 0.00 | 54.00K | 44.00 | 80.00 | 103.00 | 0.00 | 0.00 | 0.00 | 7.54K | 8.53K | 11.32K | 15.59K | 13.94K | 26.73K | 67.35K | 803.10K | 2.46M | 2.48M | 1.12M | 322.23K | 38.83K | 108.70K | 200.77K | 303.75K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 80.00K | 103.00K | 0.00 | 238.00K | 334.00K | 506.32K | 1.30M | 1.17M | 50.19K | 71.36K | 93.38K | 110.81K | 109.76K | 123.61K | 143.00K | 171.91K | 191.01K | 207.11K | 226.72K | 0.00 | 272.51K | 0.00 | 500.00K | 0.00 | 600.00K | 700.00K | 400.00K | 400.00K | 200.00K | 100.00K |
| Depreciation & Amortization | 106.00K | 102.00K | 76.00K | 68.00K | 84.00K | 54.00K | 21.00K | 10.00K | 1.13M | 1.31M | 1.06M | 991.72K | 1.21M | 1.52M | 1.69M | 1.19M | 1.17M | 1.04M | 1.44M | 1.87M | 1.01M | 402.19K | 1.89M | 2.78M | 2.05M | 2.80M | 2.10M | 1.80M | 1.50M | 1.80M | 1.50M | 800.00K | 400.00K |
| EBITDA | -10.63M | -13.18M | -11.28M | -9.02M | -7.16M | -7.19M | -5.25M | -9.63M | -897.00K | -29.66M | -24.21M | -27.45M | -20.05M | -23.63M | -25.22M | -27.79M | -23.72M | -17.76M | -10.48M | -14.10M | -11.13M | -9.81M | -9.70M | -6.48M | -7.84M | -10.70M | -12.10M | -13.90M | -6.00M | -15.10M | -10.70M | -8.90M | -6.00M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -31,291.45% | -3,052.57% | -2,637.91% | -1,545.98% | -2,702.46% | -2,212.89% | -3,029.50% | -8,966.09% | -47,746.50% | -21,219.87% | -9,056.85% | -9,551.51% | -4,080.33% | -2,352.31% | -2,189.93% | -6,180.28% | -35.76% | -136.36% | -81.13% | -232.39% | -45.76% | -1,238.46% | -356.67% | -635.71% | -1,240.00% |
| Operating Income | -9.86M | -13.28M | -11.36M | -9.09M | -7.24M | 7.24M | -5.27M | -9.64M | -36.72M | -30.91M | -28.61M | -22.55M | -27.13M | 29.36M | 29.38M | 26.74M | 28.59M | 21.37M | 16.39M | 15.40M | 12.15M | 10.21M | 11.59M | 9.27M | -9.89M | 13.50M | -14.20M | 15.70M | 7.50M | 16.90M | 12.20M | 9.70M | 6.40M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -31,384.62% | -3,054.35% | -2,377.81% | -1,648.13% | -2,222.30% | 2,057.47% | 2,958.92% | 11,538.44% | 50,405.78% | 23,016.51% | 7,958.70% | 10,919.24% | 4,442.17% | 2,458.03% | 1,438.84% | 12,470.98% | -196.94% | 153.41% | -133.96% | 221.13% | 63.56% | 1,300.00% | 406.67% | 692.86% | 1,280.00% |
| Total Other Income/Expenses | -885.00K | 113.00K | 44.00K | -80.00K | -7.00K | 4.00K | -2.32M | -28.00K | -6.00K | -31.36M | -25.63M | -6.30M | 5.81M | 4.12M | -56.40M | -55.82M | -28.59M | -40.32M | 1.82M | -2.76M | 23.76K | -10.21M | -11.59M | -9.27M | -6.05M | -13.50M | -3.50M | -15.70M | -7.50M | -16.90M | -12.20M | -9.70M | -6.40M |
| Income Before Tax | -10.74M | -13.17M | -11.31M | -9.17M | -7.25M | -7.24M | -7.59M | -9.66M | -36.41M | -32.26M | -26.44M | -28.49M | -21.33B | -25.24B | -27.03B | -29.09B | -25.02B | -18.95B | 20.09M | 15.34M | 12.17M | 10.17M | -4.02B | 7.38M | -15.94M | 14.80M | -17.70M | 18.30M | 6.90M | 17.90M | 0.00 | 0.00 | 6.60M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -31,123.08% | -3,187.85% | -2,197.76% | -2,082.76% | -1,746,808.85% | -1,769,029.18% | -2,722,049.31% | -12,552,011.82% | -44,114,809.07% | -20,407,517.50% | 9,754.91% | 10,875.51% | 4,450.86% | 2,449.13% | -499,421.53% | 9,926.20% | -317.37% | 168.18% | -166.98% | 257.75% | 58.47% | 1,376.92% | 0.00% | 0.00% | 1,320.00% |
| Income Tax Expense | 0.00 | -118.00M | -44.00K | 80.00K | 103.00K | -14.48M | 2.32M | 28.00K | -908.70K | 477.80K | -3.09M | 83.89K | -7.01M | -3.89M | -2.35M | 3.21M | -2.79M | -2.42M | -4.65M | -69.54K | 144.53K | 154.98K | -8.14M | 2.08M | 5.82M | -900.00K | 3.90M | -1.90M | 1.40M | -400.00K | 300.00K | 300.00K | 0.00 |
| Net Income | -10.74M | 104.83M | -11.27M | -9.25M | -7.35M | -7.24M | -7.59M | -9.66M | -36.42M | -32.74M | -26.44M | -28.49M | -21.33M | -25.24M | -27.03M | -29.09M | -25.02M | -18.95M | -11.74M | -15.33M | -12.29M | -10.37M | -3.45M | -11.34M | -15.71M | -12.60M | -18.10M | -13.80M | -8.90M | -16.50M | -12.50M | -10.00M | -6.40M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -31,123.93% | -3,235.28% | -2,197.76% | -2,082.76% | -1,746.76% | -1,769.03% | -2,722.05% | -12,552.01% | -44,114.81% | -20,407.52% | -5,700.61% | -10,869.93% | -4,495.03% | -2,495.34% | -428.01% | -15,264.44% | -312.81% | -143.18% | -170.75% | -194.37% | -75.42% | -1,269.23% | -416.67% | -714.29% | -1,280.00% |
| EPS | -1.05 | 14.44 | -1.59 | -1.30 | -1.72 | -2.49 | -3.48 | -10.14 | -497.22 | -860.88 | -986.42 | -1.60K | -2.44K | -3.32K | -4.13K | -5.70K | -5.08K | -4.11K | -2.99K | -5.01K | -6.21K | -6.69K | -2.51K | -9.16K | -13.61K | -11.16K | -17.49K | -14.33K | -9.51K | -24.30K | -19.35K | -20.70K | -16.45K |
| EPS Diluted | -1.05 | 14.44 | -1.59 | -1.30 | -1.72 | -2.49 | -3.48 | -10.14 | -497.22 | -860.88 | -986.42 | -1.60K | -2.44K | -3.32K | -4.13K | -5.70K | -5.08K | -4.11K | -2.99K | -5.01K | -6.21K | -6.69K | -2.38K | -9.16K | -13.58K | -11.16K | -17.49K | -14.33K | -9.51K | -24.30K | -19.35K | -20.70K | -16.45K |
| Weighted Avg Shares Out | 10.20M | 7.26M | 7.11M | 7.12M | 4.27M | 2.90M | 2.18M | 952.89K | 73.24K | 38.03K | 26.80K | 17.79K | 8.76K | 7.61K | 6.55K | 5.11K | 4.92K | 4.61K | 3.93K | 3.06K | 1.98K | 1.55K | 1.37K | 1.24K | 1.15K | 1.13K | 1.04K | 963.00 | 936.00 | 679.00 | 646.00 | 483.00 | 389.00 |
| Weighted Avg Shares Out (Dil) | 10.20M | 7.26M | 7.11M | 7.12M | 4.27M | 2.90M | 2.18M | 952.92K | 73.24K | 38.03K | 26.80K | 17.79K | 8.76K | 7.61K | 6.55K | 5.11K | 4.92K | 4.61K | 3.93K | 3.06K | 1.98K | 1.55K | 1.45K | 1.24K | 1.16K | 1.13K | 1.04K | 963.00 | 936.00 | 679.00 | 646.00 | 483.00 | 389.00 |
Microbot Medical Announces Grant of Summary Judgment in its Favor and Dismissal of Counterclaim Against Company
BRAINTREE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Robotic Surgical System, today announces that the United States District Court for the Southern District of New York, approved Microbot's motion for...
Microbot Medical Announces Successful Initial Outcomes from Its Pivotal Pre-Clinical Study with the LIBERTY® Robotic Surgical System
BRAINTREE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Robotic Surgical System, today announces the successful initial outcomes of using the LIBERTY Robotic Surgical System in its pivotal pre-clinical study.
Microbot Medical Engages CRO to Support its Upcoming U.S. Pivotal Clinical Trial
The engagement is an additional step in the Company's path towards marketing clearance with the FDA The engagement is an additional step in the Company's path towards marketing clearance with the FDA
Microbot Medical Gains Global Recognition; Professor Vincent Vidal to Present an Abstract on The LIBERTY® Robotic Surgical System at CIRSE 2023
The presentation follows successful extensive uses of the Company's endovascular robotic system in pre-clinical studies The presentation follows successful extensive uses of the Company's endovascular robotic system in pre-clinical studies
Microbot Medical Boosts Manufacturing and Commercialization Capabilities for its Robotic Surgical System
The Agreement with a leading full turnkey manufacturer further strengthens the Company's progression towards expected first in human clinical trials followed by regulatory approval and commercialization The Agreement with a leading full turnkey manufacturer further strengthens the Company's progression towards...
Microbot Medical Strengthens Its Position Among US Interventional Radiologists by Appointing Professor Francois H. Cornelis to Its Scientific Advisory Board
Professor Francois H. Cornelis is a world renown neuro interventional radiologist who specializes in minimally invasive image-guided therapies Professor Francois H. Cornelis is a world renown neuro interventional radiologist who specializes in minimally invasive image-guided therapies
Microbot Medical Engaging with a Leading Notified Body to Advance CE Mark for Sales in Europe
Engagement includes audit plans for ISO 13485 certification, to pave the way for obtaining CE Mark for clearance of sales in the European Union Engagement includes audit plans for ISO 13485 certification, to pave the way for obtaining CE Mark...
Microbot Medical Expands its Physician Support with the Addition of Leading Italian Interventional Radiologist Irene Bargellini, M.D., to its Scientific Advisory Board
Believes that the reduction in radiation exposure the LIBERTY® system could empower more women to pursue careers in Interventional Radiology Believes that the reduction in radiation exposure the LIBERTY® system could empower more women to pursue careers in Interventional Radiology
3 Undervalued Penny Stocks to Buy for Multi-Bagger Returns
The stock market can provide investors with an unpredictable and thrilling journey, filled with both excitement and anticipation. This article will delve into the peak of that exhilaration – penny stocks, and particularly high return penny stocks which may be...
Microbot Medical spikes 150% on its Endovascular Surgical Robot
Microbot Medical Inc. NASDAQ: MBOT stock spiked more than 150% on a massive 194 million share volume on a successful pre-clinical animal study for its LIBERTY surgical robotic system. Shares hit a high of $4.37 intraday before closing at $3.19...
Source: https://incomestatements.info
Category: Stock Reports